Deneen Norman
Acute Care · Saint George, UTNPI 1871662957
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,164 of the $1,308 with a category attached, or 89.0%. 11 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 26.8% of the total. Reporting peaked in 2022 at $413 and has fallen 73.0% since, to $112 in 2025.
Across 24 payments — averaging $54.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$351
- E.r. Squibb & Sons, L.L.C.$272
- Medtronic$194
- Boehringer Ingelheim$121
- Merck$119
- Medicure Pharma Inc.$84
- plus $167 from 5 others
What the payments were for
- Speaking & faculty fees$846%
- Food & beverage$1,16489%
- Education$605%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 5 | $351 |
| E.r. Squibb & Sons, L.L.C. | 6 | $272 |
| Medtronic | 2 | $194 |
| Boehringer Ingelheim | 1 | $121 |
| Merck | 2 | $119 |
| Medicure Pharma Inc. | 1 | $84 |
| Johnson & Johnson | 1 | $58 |
| Boston Scientific | 2 | $40 |
| Novartis | 2 | $28 |
| Amgen | 1 | $26 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,308 in reported general payments places this provider in the 85th percentile of 119 acute care providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $187,379 |
| XareltoRivaroxaban | 17 | $23,308 |
| EntrestoSacubitril/Valsartan | 18 | $21,804 |
| JardianceEmpagliflozin | 14 | $15,841 |
| Metoprolol Succinate | 185 | $2,840 |
| Atorvastatin Calcium | 234 | $2,197 |
| Rosuvastatin Calcium | 170 | $2,136 |
| Flecainide Acetate | 62 | $2,053 |
| Amiodarone Hcl | 90 | $1,726 |
| Losartan Potassium | 128 | $1,596 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 80 | $1,411 |
| Carvedilol | 121 | $1,399 |
| Spironolactone | 131 | $1,198 |
| ClopidogrelClopidogrel Bisulfate | 117 | $1,158 |
| SotalolSotalol Hcl | 33 | $1,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $187,379169 claims |
| Johnson & JohnsonXarelto | $58 | $23,30817 claims |
| NovartisEntresto | $28 | $21,80418 claims |
| Boehringer IngelheimJardiance | $121 | $15,84114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 119 acute care providers in Utah.
Other acute care in Saint George
- Marcia DavisSaint George$774
- Jan DavisOgden$90K
- Kristina GibsonMurray$82K
- Kali DaytonMidvale$17K
- Evangeline LindorfProvo$8K
- Florin ButucMurray$4K
- Chia-Hsuan LinMurray$3K
- Cory HesterMurray$2K
- Karleena SnowSalt Lake City$2K
- Kristi KissellSalt Lake City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.